Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000638118 | SCV000759603 | uncertain significance | Parathyroid carcinoma | 2024-01-10 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 462 of the CDC73 protein (p.Pro462Ser). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CDC73-related conditions. ClinVar contains an entry for this variant (Variation ID: 531646). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV001011271 | SCV001171571 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-11-14 | criteria provided, single submitter | clinical testing | The p.P462S variant (also known as c.1384C>T), located in coding exon 15 of the CDC73 gene, results from a C to T substitution at nucleotide position 1384. The proline at codon 462 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Baylor Genetics | RCV003459526 | SCV004215593 | uncertain significance | Hyperparathyroidism 1 | 2023-05-01 | criteria provided, single submitter | clinical testing |